Development of a preliminary composite disease activity index in psoriatic arthritis

被引:164
作者
Mumtaz, Aizad
Gallagher, Phil
Kirby, Brian [2 ]
Waxman, Robin [3 ]
Coates, Laura C. [3 ]
Veale, Douglas J.
Helliwell, Philip [3 ]
FitzGerald, Oliver [1 ]
机构
[1] St Vincents Univ Hosp, Univ Coll Dublin, Dublin Acad Hlth Care, Bone & Joint Unit,Dept Rheumatol, Dublin 4, Ireland
[2] St Vincents Univ Hosp, Dept Dermatol, Dublin 4, Ireland
[3] Univ Leeds, Leeds Inst Mol Med, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England
关键词
QUALITY-OF-LIFE; ANKYLOSING-SPONDYLITIS; CLASSIFICATION; RELIABILITY; ADALIMUMAB; PLACEBO;
D O I
10.1136/ard.2010.129379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis. Methods Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0-15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated. Results Significant correlation was seen between CPDAI and both patient (r= 0.834) and physician (r = 0.825) global disease activity assessments (p = 0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5. Conclusion CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 30 条
  • [1] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    Antoni, C
    Krueger, GG
    de Vlam, K
    Birbara, C
    Beutler, A
    Guzzo, C
    Zhou, B
    Dooley, LT
    Kavanaugh, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1150 - 1157
  • [2] Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185
  • [3] Battistone MJ, 1998, J RHEUMATOL, V25, P2395
  • [4] International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
    Braun, J
    Pham, T
    Sieper, J
    Davis, J
    van der Linden, S
    Dougados, M
    van der Heijde, D
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) : 817 - 824
  • [5] Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis - A Department of Veterans Affairs cooperative study
    Clegg, DO
    Reda, DJ
    Mejias, E
    Cannon, GW
    Weisman, MH
    Taylor, T
    BudimanMak, E
    Blackburn, WD
    Vasey, FB
    Mahowald, ML
    Cush, JJ
    Schumacher, HR
    Silverman, SL
    Alepa, FP
    Luggen, ME
    Cohen, MR
    Makkena, R
    Haakenson, CM
    Ward, RH
    Manaster, BJ
    Anderson, RJ
    Ward, JR
    Henderson, WG
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (12): : 2013 - 2020
  • [6] Health-related quality of life outcomes in patients with active Ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study
    Davis, John C., Jr.
    Revicki, Dennis
    van der Heijde, Desiree M. F.
    Rentz, Anne M.
    Wong, Robert L.
    Kupper, Hartmut
    Luo, Michelle P.
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (06): : 1050 - 1057
  • [7] Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
    Doward, LC
    Spoorenberg, A
    Cook, SA
    Whalley, D
    Helliwell, PS
    Kay, LJ
    McKenna, SP
    Tennant, A
    van der Heijde, D
    Chamberlain, MA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (01) : 20 - 26
  • [8] DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE
    FINLAY, AY
    KHAN, GK
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) : 210 - 216
  • [9] SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID
    FREDRIKSSON, T
    PETTERSSON, U
    [J]. DERMATOLOGICA, 1978, 157 (04): : 238 - 244
  • [10] MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS
    FRIES, JF
    SPITZ, P
    KRAINES, RG
    HOLMAN, HR
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (02): : 137 - 145